Silexion Therapeutics Ltd. (SLXN) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.27
↓-73% vs avg
5yr avg: 0.98
30Y Low1.0·High1.0
ROE
↓
-457.6%
↑-195% vs avg
5yr avg: -155.0%
30Y Low-458%·High-1%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SLXN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Silexion Therapeutics Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $3M | $188M | — | — | — | — |
| Enterprise Value | $-3900268 | $-2970331 | $191M | — | — | — | — |
| P/E Ratio → | -0.06 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 0.27 | 0.98 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SLXN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
SLXN Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -457.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -457.6% | -457.6% | — | — | -6.0% | -1.3% | — |
| ROA | -236.4% | -236.4% | -405.0% | -67.7% | -5.2% | -1.3% | -151.4% |
| ROIC | — | — | — | — | -5.8% | -1.2% | — |
| ROCE | -612.7% | -612.7% | -1047.6% | -86.8% | -6.3% | -1.6% | -195.9% |
SLXN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $6M exceeds total debt of $468000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.12 | — | — | — | -0.00 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -241.75 | -520.11 | -45.41 | — | — |
Net cash position: cash ($6M) exceeds total debt ($468000)
SLXN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Silexion Therapeutics Ltd.'s current ratio of 2.41x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.27x to 2.41x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.41 | 2.41 | 0.64 | 2.27 | 5.49 | 1.17 | 1.76 |
| Quick Ratio | 2.41 | 2.41 | 0.64 | 2.27 | 5.49 | 1.17 | 1.76 |
| Cash Ratio | 2.17 | 2.17 | 0.34 | 2.09 | 5.13 | 0.11 | 1.76 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
SLXN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Silexion Therapeutics Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $1M | $6M | $1M | $17M | $17M | $17M |
Peer Comparison
Compare SLXN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SLXNYou | $2M | -0.1 | — | — | — | — | -457.6% | — | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 MRNA | $19B | -6.7 | — | — | 55.3% | -158.1% | -28.9% | -26.1% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See SLXN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLXN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLXN vs SRPT
Side-by-side business, growth, and profitability comparison vs Sarepta Therapeutics, Inc..
Start ComparisonSLXN — Frequently Asked Questions
Quick answers to the most common questions about buying SLXN stock.
What is Silexion Therapeutics Ltd.'s P/E ratio?
Silexion Therapeutics Ltd.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Silexion Therapeutics Ltd.'s ROE?
Silexion Therapeutics Ltd.'s return on equity (ROE) is -457.6%. The historical average is -155.0%.
Is SLXN stock overvalued?
Based on historical data, Silexion Therapeutics Ltd. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.